SAN DIEGO (AP) — Cadence Pharmaceuticals Inc. said Wednesday the FDA will give the company’s painkiller candidate and expedited regulatory review. The company said the FDA will review Acetavance, a form of the painkiller acetaminophen that is given intravenously, under a priority review. The designation cuts the planned review period to 6 months from the standard 10 months. The FDA is scheduled to make a regulatory decision by Nov. 13.
Related Articles Read More >

Confidently navigate the transition from bench to batch

FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension

Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
